Andecaliximab

Drug Profile

Andecaliximab

Alternative Names: Anti-matrix metalloproteinase-9 monoclonal antibody; Anti-MMP9 monoclonal antibody; GS-5745; MMP9 mAb inhibitor

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastric cancer
  • Phase I Solid tumours
  • Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 28 Oct 2017 Adverse events and efficacy data from a phase II trial in Crohn's disease presented at the 25th United European Gastroenterology Week (UEGW-2017)
  • 28 Oct 2017 Efficacy and adverse events data from a phase II/III trial in Ulcerative colitis presented at the 25th United European Gastroenterology Week (UEGW-2017)
  • 31 Aug 2017 Discontinued - Phase-I for Chronic obstructive pulmonary disease in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top